Phased RF Ablation: Results and Concerns
Alexandra Kiss, MD, PhD, Gábor Sándorfi, MD, Edina Nagy-Baló, MD, PhD, Mihran Martirosyan, MD, Zoltan Csanadi, MD, PhD
Department of Cardiology, University of Debrecen, Debrecen, Hungary.
Treatment of atrial fibrillation (AF) with catheter ablation has proven to be a safe and effective treatment modality which is offered to an increasing number of patients in many centers. Pulmonary vein isolation (PVI) is an established cornerstone of AF ablation strategies. Athough the isolation of the pulmonary veins (PVs) with irrigated focal radiofrequency (RF) catheters using a point-by-point method is considered as the gold standard, it can be challenging to create contiguous lesions, time consuming, and require advanced three dimensional (3D) mapping and navigational systems. The phased RF ablation system was designed to address many of these challenges associated with conventional focal RF ablation. In this review, we describe the main features of phased RF ablation and summarize the data available on clinical outcome with this technology.
Corresponding Address : Dr. Zoltan Csanadi
22 Móricz, Debrecen
H-4032, Hungary.
Catheter ablation for AF has emerged as an alternative to antiarrhythmic drug (AAD) therapy after the failure of at least one AAD, or even as the first line of treatment in selected cases.1-3 Although a wide variety of ablation techniques have been used to treat AF, it is generally agreed that the cornerstone of any transcatheter procedure is the electrical isolation of all PVs. This is currently most commonly achieved by encircling the PVs with focal RF lesions under the guidance of a 3D electroanatomical mapping or navigation system.4 This point-by-point ablation technique requires extensive operator experience for efficiency and safety, and is usually associated with long procedure times, especially in centers with limited experience. Novel methods aiming at simpler and faster PVI have therefore been developed in recent years, including balloon-based technologies.
Cryoballoon (CB) ablation was the first introduced5-6 and continues to be utilized routinely in many centers. The laser balloon has also been accepted and is becoming used increasingly in even more laboratories.7 Only limited clinical data are available with the ”hot” RF balloon,8 while the high-intensity focused ultrasound balloon has been removed from clinical practice after lethal complications.9 The common concept of these ”single-shot” AF ablation technologies is the creation of circular lesions for PVI by placing the ablation device at the antrum or ostium of the PVs without the need for continuous repositioning.
The phased RF ablation system was also designed to address many of the challenges associated with conventional focal catheter ablation. Specifically, the system utilizes anatomically designed, multi-electrode catheters with tissue temperature monitoring and a closed-loop power control generator to create contiguous, transmural lesions.10
Phased RF Ablation Technique
The phased RF AF ablation catheter family consists of 3 catheters (Fig. 1).
Figure 1. The phased RF catheter family and the GeniousTM RF generator. See text for details. (Image courtesy of Medtronic Inc)
The circular multipolar pulmomary vein ablation catheter (PVAC; Medtronic Inc, Minneapolis, MN, USA) was designed to create antral lesions of the PVs and provide distal mapping and pacing to assess PVI. The original version of the PVAC consisted of a 25-mm helical electrode array with 10 platinum electrodes and over-the-wire tracking for enhanced PV targeting and placement stability. Most of the published data reflect the experience with this device, which was recently replaced by the PVAC Gold catheter which contains 9 gold electrodes. Gold has more than 4 times better thermal conductivity than that of platinum, thereby providing faster cooling and more precise temperature control. The number of electrodes was reduced in order to eliminate the potential bipolar short circuit between electrodes 1 and 10, which did occur with the previous PVAC, as discussed later. Further, a 20-degree forward tilt was added to the distal circular segment of the new PVAC Gold catheter for a more uniform contact with the PV antrum.
The multiarray septal catheter (MASC™, Medtronic Inc, Minneapolis, MN, USA) is designed to map and ablate the atrial septal wall. It has 12 platinum electrodes on the underside of the array, with fins for added cooling. After the MASC has been introduced through the transseptal puncture site, the electrodes are positioned against the septum by pulling back on the catheter.
The multiarray ablation catheter (MAAC™, Medtronic Inc, Minneapolis, MN, USA) is designed to map and ablate arrhythmogenic drivers in the left atrial (LA) body, such as complex fractionated atrial electrograms (CFAEs). It is composed of 8 finned platinum electrodes affixed to an X-shaped nitinol frame, with 2 electrodes on each arm.
All three catheters monitor electrode-tissue temperature through thermocouples bonded directly to each electrode on the side of the electrode in contact with the tissue. Thermocouples are placed as close as possible to the tissue interface for more accurate temperature monitoring.
A unique feature of the system is the duty-cycled phased RF energy,
which is used for lesion formation with all 3 catheters. The GENius™
Multi-Channel RF Ablation Generator (Medtronic, Minneapolis
MN, USA) contains 12 independently controlled RF generators for
each electrode in the catheter. It monitors the temperature on each
electrode and adapts the power to achieve and maintain the target
temperature (nominally 60 °C). Power regulation is achieved through
duty-cycling of the RF energy, rather than voltage control (Fig. 2.)
The time period with no RF delivery, allows accurate temperature
monitoring and provides time for the electrode to cool between RF
bursts. The multi-electrode catheter design and the generator facilitate
simultaneous bipolar (between the electrodes) and unipolar (from the
electrode to the ground pad) delivery of energy (Fig. 3). Unipolar RF
delivery results in deeper lesions, while bipolar application facilitates
lesions between electrodes. The generator allows the operator to
select between different ratios of simultaneous unipolar and bipolar
energy delivery including unipolar only, 1:1, 2:1, 4:1, or bipolar only.
For example, the 4:1 energy mode indicates that 80% of the energy delivered is bipolar and the remaining 20% is unipolar. The results of
bench tests indicated that the depth of the lesions was proportional to
the energy mode selected, with unipolar delivery causing the deepest
lesions, followed by 1:1, 2:1, 4:1 and bipolar RF application, the latter
causing the shallowest lesions.11 The GENius™ monitors the power
and the temperature on each electrode and displays to the operator
when the power and temperature are sufficient to create a good lesion
(Contact IQ). The bars are yellow if the temperature or the power is
too low to cause a lesion, and green when the power and temperature
are sufficient for better lesion creation (>3 W and > 50 °C) which has
been associated with a better clinical outcome.
Figure 2. Duty-cycling of RF energy. While continuous RF energy is delivered during conventional RF ablation, “on” and “off” periods alternate during duty-cycled ablation. The length of the “on” time is regulated to reach and maintain the target temperature. The time period with no RF delivery allows accurate temperature monitoring and provides time for the electrode to cool between RF bursts. (Image courtesy of Medtronic Inc)
Figure 3. The concept of unipolar and bipolar energy delivery (phasing). The multi-electrode catheter design and the generator enable simultaneous bipolar (between electrodes) as well as unipolar (from electrode to ground pad) delivery of RF energy. There is no voltage difference thus no current flow between neighbouring electrodes while “in phase”, so only unipolar energy is delivered between each electrode and the ground pad (left). When the voltages for the two adjacent electrodes are “out of phase” (right), interelectrode voltage difference results in bipolar RF delivery. Different ratios of simultaneous unipolar and bipolar energy delivery including unipolar only, 1:1, 2:1, 4:1, or bipolar only can be selected. (Image courtesy of Medtronic Inc)
Phased RF ablation procedures require a single transseptal puncture
and a standard or a stearable transseptal sheath to guide the ablation
catheter. Recent recommendations on periprocedural anticoagulation
include uninterrupted vitamin K antagonist (VKA) administration
for at least 1 month before the procedure and a therapeutic(2-3)
INR on the day of the ablation. A heparin iv bolus is administered
before or immediately after the transseptal puncture and repeated
as required to reach and maintain a target INR level above 350 sec
throughout the left atrial access period.
The PVAC or PVAC Gold catheter is used to isolate and then
validate the elecrical isolation of all PVs. The catheter is introduced
into the sheath with the spiral array extended over a guidewire
(0.032 inches in diameter, at least 180 cm in length) through use of a
sliding knob on the catheter handle. Passing the valve of the sheath
is facilitated by a tube-shaped capture device provided with the
catheter. It is recommended to capture the 3-dimensional distal part
containing the electrodes under saline in order to eliminate any air
bubble possibly trapped within the complex structure of the electrode
array. The catheter is advanced through the guiding sheath over the
guidewire positioned in one of the PVs. When it enters the LA, the
sliding knob is retracted to allow the electrode array to regain its
circular shape. Positioning the electrodes at the PV antra is facilitated
by the guidewire in the PV being advanced beyond the border of the
cardiac silhouette, which also promotes the maintenance of a stable position during RF deliveries. PV angiography through the guiding
sheath can be used to assess the catheter position in relation to the
ostium so as to avoid any RF application inside the PVs. Catheter
placement with stable tissue contact on as many electrodes as possible
as assessed via the electrogram is preferred. RF energy is applied for
60 sec, usually with a starting bipolar:unipolar ratio of 4:1 or 2:1. It
is recommended to switch off any electrode pair that fails to reach at
least 50 oC during RF delivery in order to in order to avoid ineffective
applications due to improper contact at the electrode-tissue interface.
Furthermore, when an electrode reaches the target temperature while
delivering very low power (1-2 W), it is considered a sign of an
undesirably strong electrode-tissue contact or a wedge position of
the electrode, and energy delivery to that particular electrode should
be switched off.
Figure 4. The PVAC and the PVAC Gold positioned in the pulmonary veins. PVAC Gold (9 electrodes) is positioned in the lateral, PVAC (10 platinum electrodes) in the septal pulmonary veins. Note the overlap between poles 1 and 10 of the PVAC in the right inferior vein and a „safe” interelectrode distance in the right superior vein (arrows). See text for explanation
As electrograms can not be assessed during the delivery of phased
RF current because of electrical noise, electrical conduction of the
PVs can be assessed between the applications. It is inherent to the
electrode design that the intracardiac signals recorded with this
circular catheter are smoothed, less detailed and lower in amplitude
than those recorded with conventional circular mapping catheters
(Fig. 5). Duytschaever reported a 93% overall diagnostic accuracy
for the verification of PVI when a conventional mapping catheter
was used as a gold standard.12 Pacing maneuvers or a conventional
mapping catheter should be considered whenever doubt remains
about PV conduction.13
Figure 5. Pulmonary vein potentials recorded by the PVAC from the left superior pulmonary vein during continuous stimulation in the coronary sinus. Pacing artefacts are followed by atrialelectrograms and pulmonary vein potentials (*)
Besides PVI, phased RF ablation of atrial tissue at sites
demonstrating CFAEs can be performed through use of the MASC
and MAAC devices. The MASC is designed to ablate the septum in
response to pulling on the catheter and the transseptal sheath and
holding the electrode against the septum. Between RF applications
the catheter can be rotated to cover another area of the septum. The
MAAC catheter is designed to ablate other sites of the LA, including the posterior wall.
A significant limitation of current phased RF technology is that due
to the many anatomical variations it may be difficult to have a stable
tissue contact with these multipolar catheters even after different
kinds of maneuvers. Recent data suggest that the inclusion of contact
force sensors significantly improves reliability and safety therefore
this technology is now considered by many electrophysiologists as
the gold standard for left atrial ablation. Phased RF ablation will
likely be of greater interest once it has this extra function
Clinical Results with Phased RF Ablation
Acute Success and Procedural Parameters
Procedural outcomes and follow-up results from some singlecenter
studies are presented in Table 1.14-24 On the basis of a
metaanalysis of 42 publications, Andrade et al.25 reported an average
procedure time of 116.9±33 min and a fluoroscopy time of 26.5±9.6
min with 25.1±3.4 applications per procedure on use of the PVAC
only in patients with paroxysmal AF. Procedure and fluoroscopy
times for ablations with the PVAC, MASC and MAAC in persistent
AF patients were 137.1±29.3 and 31.6±12.4 min, respectively. The
data on 1147 patients from 20 studies indicated that acute PVI was
achieved with the PVAC alone, without concomitant use of a focal
RF ablation catheter, in 98.57% of the patients and in 99.38% of the
targeted PVs. It should be noted that mean procedure times below
85 min have been reported from experienced centers for a cohort of
paroxysmal14 or mostly paroxysmal AF patients.15
Table 1. Acute and longer-term results of phased RF ablation
| Study | No.of
Pts | Age | Type of AF parox:
persistent (%) | Mean Left atrial
diameter(mm) | Proc. time
(min) | Fluoro time
(min) | Additional
ablation | Acute success
rate (%) | Months of FU | Long term
success (%) |
|---|
| Boersma et al. 14 | 98 | 59±9 | 100:0 | na | 84±29 | 18±9 | - | 100 | 6 | 83 |
| Fredesrdorf et al.15 | 21 | 59±12 | 80:20 | na | 81±13 | 30±11 | - | 99 | 6 | 86 |
| Scharf et al. 16 | 50 | 58±7 | long-standing
persistent | 46±5 | 155±40 | 55±35 | MASC+MAAC | 100 | 6.3±0.9 | 70 |
| Beukema et al.17 | 102 | 57.9±9.6 | 90:12 | 41.2±6.5 | 139.3±37.72 | 32.1±11.3 | irrigated RF if
needed | 100 | 12.2±3.9 | 60.8 |
| Wieczorek et al.18 | 88 | 58±11 | 100:0 | 44±4 | 125±28 | 21±13 | RF | 99 | >3 and <12 ≥12 | 82.2 79.2 |
| Duytschaever et al. 19 | 77 | 60±8 | 100:0 | 41±4 | 176±25 | na | - | 97 | 3 | 74 |
| Wieczorek et al. 20 | 73 | 56±12 | 100:0 | 44±3 | 122±27 | 20±11 | RF if needed | 99 | 6 | 85 |
| Mulder et al. 21 | 89 | 59±8 | long-standing
persistent | 42±4 | 112±32 | 21±10 | MASC+MAAC | 100 | 12 | 49 |
| Mulder et al. 22 | 120 | 59 | 100:0 | 40±5 | 86±26 | na | - | 100 | 24 | 49 |
| Mulder et al. 23 | 100 | 59±9 | 100:0 | 40±5 | na | na | - | 100 | 12 | 53 |
| Nardi et al. 24 | 429 | 60±12 | 68:32 | na | 62±15 | na | 75 patients had
2 procedures | na | 22±5 | 68.5 |
Scharf et al. reported results of a survey on 2748 patients treated
with phased RF ablation for mostly paroxysmal AF in 20 European
centers.26 In 1669 paroxysmal AF patients, the overall, the first
procedure and the AAD-free success rates during a mean followup
of 11.2 months were 82% 58% and 59% respectively. Similar
results were reported from a high-volume center.22 arrhythmia-free
survival after a single procedure without AAD in 120 paroxysmal AF
patients was 55% at 1 year and 49% at 2 years. In another analysis by
the same group,21 the PV anatomy did not have a significant effect on
the long-term results; only a tendency to a poorer outcome was seen
for PVs with diameters > 24 mm.
The Tailored Treatment of Persistent Atrial Fibrillation (TTOPAF)
trial, a randomized, multicenter study involving 210 patients
with persistent AF, compared the effectiveness and safety of phased
RF ablation with AAD.27 All the patients in the ablation group were
treated with the PVAC, the MASC and the MAAC. The chronic effectiveness criterion (defined as the acute isolation of all PVs, a
50 % reduction of CFAE targets, restoration of stable SR at the
end of the ablation, and a > 90% reduction in the cumulative atrial
arrhythmia (atrial flutter or AF lasting > 10 minutes) time on the 48-
hour monitor 6 months postablation as compared with the baseline
in the absence of AAD therapy was met in 57.6% of the patients. In
the 620 patients treated for persistent/long-standing persistent AF
in the European survey.26 the overall, first procedure and AAD-free
success rates at 11.2 months postablation were 70%, 58% and 58%.
The efficacy data of the European survey were also analyzed with
respect to the level of experience of the centers reporting the data.
Importantly, the overall and first procedure success rates were similar
among the higher (79.1% and 68.8%) and lower volume (79.4% and
72.3%) centers. However, a poorer success rate was reported off AAD
in the lower- volume centers (49.7%) than in the higher-volume
centers (60.8%). Further, the success rates did not either depend
on the duration of experience with phased RF ablation or on the
number of phased RF procedures performed. Our group reported
similar findings:28 neither the success rate nor the complication rate
differed during the 1st, the 2nd and the 3rd 44 patients treated with
phased RF ablation at our center.
PVAC Ablation Outcomes in Comparison with Focal RF Ablation
PVAC ablation has been compared with focal RF ablation guided by electroanatomical mapping (Table 2) in a number of single-center
studies.29-38 Significantly lower procedure times were consistently
reported with phased RF, while the fluoroscopy times were similar
or also shorter when the PVAC was used. No difference in efficacy
was reported in these trials which involved relatively small numbers
of patients and a variable length of follow-up. A comparison of the
results of the worldwide survey39 of procedures in which focal RF
ablation was performed in the majority of patients with the data from
the European Survey on phased RF ablation26 likewise suggests a
similar outcome with the two techniques. In the first randomized
multicenter trial in which PVI with electroanatomically guided widearea
circumferential ablation (WACA; 92 patients) was compared
with use of a focal irrigated RF catheter (94 patients), the AF-free
survival at 12 months was 56% and 60% respectively.38 Both the
procedure time and the fluoroscopy time were significantly shorter
with the PVAC.
A comparison of these 2 technologies as the initial experience with
AF ablation in a lower-volume center has also been reported.30 The
first 109 patients undergoing PVI at this center were randomized
for 3D mapping-guided focal RF or for phased RF ablation. The
6-month success rate was significantly higher with the PVAC (68%)
than with focal ablation (39%), while the complication rates were
similar. The procedure and fluoroscopy times were also significantly
shorter with phased RF ablation. Although the number of these
patients is limited, these data suggest that the influence of operator
experience on the clinical success and procedural complications may
be less significant during PVI with the PVAC as compared with focal
RF ablations.
Complications with Phased RF Ablation
The risk of cerebral embolization arose as a significant concern
relatively early after this technology was introduced in clinical
practice. The TTOP-AF40 study demonstrated a 2.3% acute stroke
rate (4/176) in all ablated patients and a per-procedure incidence of
1.7% (4/239). Although the study was published only in 2014, data
were presented to the Food and Drug Admininstration in 2011, and
the results therefore received publicity earlier. It is noteworthy that
strokes occurred within 12 hours postablation on a subtherapeutic
INR level in all the patients in the TTOP-AF study suggesting that not necessarily the ablation technology per se, but rather inadequate
anticoagulation may possibly have contributed to these cerebral events.
The results of the recently published COMPARE40 trial underscores
the critical importance of periprocedural anticoagulation: pointby-
point RF antrum isolation with or without CFAE ablation was
associated with a symptomatic periprocedural thromboembolic event
rate of 4.9% when warfarin was discontinued with heparinbridging
as compared with a 0.33% event rate on uninterrupted warfarin
therapy. The majority of thromboembolic events occurred in nonparoxysmal
AF patients. Following the completion of the TTOP-AF
study, more favorable safety results were published by a center with
extensive experience in phased RF ablation: 2 strokes and 5 transient
ischemic attacks (TIAs) occurred during 662 procedures (with
use of the PVAC alone in the majority of procedures) in patients
with paroxysmal and persistent AF.22 Cerebral ischemic events also
occurred within 24 hours postablation in this study in 6 of the 7
patients, the INR during the procedure was <2.0 in 3 of them. In
the European survey on phased RF ablation in 2748 patients, a total
stroke and TIA incedence of 1,1% was reported.26 In a metaanalysis of 42 papers which included the data on 1162 patients treated for
paroxysmal and 347 patients with persistent AF, the incidence of
thromboembolic complications was 0.63%, including 6 strokes, 2
TIAs and 2 myocardial infarctions.25 In the prospective multicenter
trial in which electroanatomically guided WACA was compared with
PVAC ablation, 2 strokes (2%) occurred in the latter group, both
within 48 hours after the ablation, with heparin-bridging strategy
applied in both.38
Besides clinically manifest strokes, AF ablation might also result in
a clinically silent cerebral embolism. Silent cerebral ischemia (SCI)
can be detected by diffusion-weighted (DW) magnetic resonance
imaging (MRI) after the ablation procedure.41-46 The SCIs frequently
appear at multiple locations which are not related to a certain vascular
territory but represent different vascular distributions, suggesting the
embolic nature of these lesions. The reported rate of postablation SCIs
is highly variable, ranging from 1.7% (11) to 38.9%. In the earlier
publications, a significant correlation was demonstrated between the
incidence of these lesions and the ablation technology, with phased RF
ablation consistently posing the highest risk. Siklódy et al. reported an SCI incidence of 33% in 24 AF patients after ablation with the
PVAC, as compared with 7.4% and 4.3% in those ablated with focal
irrigated RF and the CB technology, respectively.44 Similarly, Gaita et
al. found a significantly higher SCI rate after PVAC ablation (38.9%)
as compared with irrigated RF or CB (8.3% and 5.6% respectively)45
Although 2/3 of the lesions were at most 3 mm in diameter and
the majority, (especially the smaller ones) disappeared within days
or weeks after ablation,47 the phenomenon generated significant
concern as regards the potential long-term consequences on the
cognitive function of these patients.48-49 In line with the MRI results,
intraoperative transcranial Doppler (TCD) detection of cerebral
microembolization also indicated a technology-related difference:
our group recorded a significantly higher number of mostly gaseous
microembolic signals (MESs) during PVI with the PVAC than with
CB.50 It may be noted that the majority of MESs were associated
with the energy delivery phase of PVAC ablations, while a relatively
even distribution was demonstrated during CB ablation.
Lower SCI rates have been reported with the phased RF
technology in more recent publications,51-52 and a cerebral lesion was
demonstrated in only 1 of 60 patients in the ERACE multicenter
trial, which enrolled patients with paroxysmal AF who underwent
PVI with the PVAC.53 The significant reduction achieved in clinically
silent microembolization as demonstrated by these DW MRI studies
might be attributed to the strict periprocedural anticoagulation,
including the use of uninterrupted VKA before the procedure and
heparin administration to reach an ACT target > 350 sec during
ablation. Further, on the basis of the preclinical data, refinements
in specific technical elements of the phased RF ablation have been
implemented. In an animal model, Haines observed significantly
enhanced microembolization with blended unipolar:bipolar energy
delivered through PVAC electrodes in close proximity to each
other, which was a likely common scenario, thanks to the squeezed
position of the distal PVAC loop.54-55 While actual physical contact
between any two electrodes results in an electrical short circuit and
the termination of RF delivery, a reduced interelectrode distance (less
than the fixed 3 mm between two neighboring electrodes mounted
on the distal circular segment of the PVAC) without contact may
lead to blood and tissue overheating, due to a high current density
during the RF delivery. Simple measures to avoid this possibility
include a careful fluoroscopic assessment of the electrode positions,
exclusion of simultaneous RF delivery to electrodes 1 and 10, and a
software modification implemented in the GENius generator, which
supports simultaneous RF delivery to a maximum of 9 electrodes.
In keeping with this concept, the number of electrodes on the new
PVAC Gold catheter is limited to 9. Animal data also pointed to
a tendency for more microemboli with more bipolar RF delivery.
It is therefore reasonable to change the earlier practice of starting
the energy delivery in 4:1 bipolar:unipolar mode at each PV, and
begin with a 2:1 ratio, the current practice in most centers. The
animal model also revealed that the introduction of air into the LA
via the transseptal sheath potential was a potential source of gaseous
emboli. A significantly larger air volume was measured during the
introduction of the PVAC, possibly because of its more complex
shape as compared with that of a conventional focal RF catheter.
To prevent air entrapment, submerged capture of the electrode
array in a saline bath prior to insertion into the FlexCath sheath is
recommended.
Besides the procedural changes described above, the GENius RF generator has also been modified in recent years. An improved
energy titration algorithm was implemented which regulates the
power delivery to control the maximum, instead of the average
temperature, with a target of 60 °C. Further, this software ensures a
gradual and limited increase (4 W/s) during variable or intermittent
electrode-tissue contact, thereby avoiding high temperature peaks.
The importance of the catheter-tissue contact has been stressed since
the introduction of contact force measurement for focal RF ablation
catheters.56 With multipolar ablation, this becomes even more critical,
as the maintenance of good contact simultaneously on multiple
electrodes can be challenging, and the possibility of direct contact
force measurement with this technology is not yet available. This
concept is supported by our previous study: an analysis of temperature
and power data obtained at high-resolution sampling from the
GENius generator demostrated increased microembolus formation
during intermittent contact scenarios when low temperature was
compensated by increased power, which resulted in a temperature
overshoot when the contact was re-established.57 Further, in the
most recent issue of the GENius software, RF delivery is limited
to 9 electrodes, thereby providing a definite solution regarding the
problem of E1-E10 interaction.
Similarly to the trend observed in recent DW MRI studies on the
rate of new SCI lesions after phased RF ablation, our group observed
a significant decrease in the number of cerebral MESs detected by
TCD.58 A Comparison of cerebral microembolization during PVAC
ablations before and after the procedural changes discussed above
were implemented at our center revealed a significant decrease to
the level obtained with a CB (Fig. 6). The significant reduction
in microembolization with phased RF was clearly related to the
elimination of the MESs during the energy delivery period of the
procedure. It is noteworthy that the MESs were largely gaseous in
nature in all the treatment groups.
Figure 6. Incidence of silent cerebral lesions detected by DW MRI in different studies with cryoballoon (blue), irrigated RF (yellow) and phased RF (blue)
Other potential complications during phased RF ablation are
similar to what may occur during left atrial ablation with any other
technology and include problems at vascular access sites, pericardial
tamponade and PV stenosis.
In the meta-analysis by Andrade et al., 3 pericardial tamponades
and 3 effusions were reported in 1719 patients; 1 out of 931 patients
exhibited symptomatic PV stenosis.25 A higher incidence of PV
stenosis at long-term follow-up emerged in a recent study.59 A
25-50%-degree stenosis was found in 37%, one of 50-70 % in 9%
and one of > 70% in 3% of the patients. However, these mostly mildto-
moderate narrowings resulted in no symptoms and ventilation/
scans demonstrated no abnormalities. Clinically relevant injury to
the esophagus, one of the most feared complications of AF ablation
with high mortality and phrenic nerve palsy, has never been reported
with phased RF ablation.
Table 2. Phased RF ablation outcomes in comparison with focal RF ablation
| Study | No.of Pts | Age | Paroxysmal: Persistent: Long standing AF (%) | Left atrial diameter (mm) | Procedure time (min) | Fluoro time (min) | Acute success rate (%) | Length of FU | Long term success (%) |
|---|
| Bulava et al. 29 | PVAC: 51 RF+ Carto: 51 | 56.5±9.9 59.8±11.9 | paroxysmal | 41.2±5.4 39.7±4.4 | 107±31 208±46 | 16±5 28±8 | 98 98.5 | 202±13 days | 77 71 |
| Choo et al. 30 | PVAC: 38
RF+Carto: 47 RF+NavX: 24 RF+3D Mapping: 71
| 56.9±10.2 56.2±10.5 62.2±7.7 58.2±10.2 | 79:2:0 60:40:0 63:37:0 39:61:0 | 42.0±7.5 40.5±7.5 43.9±6.3 41.5±7.3 | 168±41 246±60 265±60 252±60 | 39±14 73±27 79±25 75±26 | 97 96 100 97 | 6 months | 68 40 38 39 |
| Bittner et al. 31 | PVAC: 40 RF+3D Mapping: 40 | 57±11 59±9 | 53:47:0 58:42:0 | 43±5 42±7 | 171±40 224±27 | 26±8 35±9 | 99 100 | 254±99 days | 254±99 days | 254±99 days |
| Khaykin et al. 32 | PVAC: 31 RF+3D Mapping: 19 | 63±10 57±12 | paroxysmal | 39±6 43±4 | 125±25 135±26 | 36±14 50±16 | na na | 6 months | 67 54 |
| Spitzer et al. 33 | PVAC: 388 RF+NavX:151 | 61.7±9.7 58.1±9.3 | 79.9 :17.5: 2.6 54.3 :31.1:14.6 | 42±6 43±5 | 67.0±18.0 142.2±35.0 | 15.6±5.7 29.3±9.8 | >99 >99 | 24months | 64.2 48.2 |
| De Greef et al. 34 | PVAC: 79
RF+Carto: 82
| 60±10 58±10 | 66:34:0 55:45:0 | 41±7 42±7 | 121±41 169±43 | 33±11 32±15 | 100 100 | 3 years | 65 55 |
| Tivig et al.35 | PVAC: 143 PVAC: 66 RF+NavX :155 RF+NavX:56 | 61±10 61±10 58.8±10 61±9 | paroxysmal persistent paroxysmal persistent | 40±6 46±6 40±5 47±7 | 128±38 171±39 134±43 161±44 | 29±13 46±14 39±20 44±18 | na na na na | 12months | 76 55 71 52 |
| Looi et al.36 | PVAC: 75
RF+Carto: 128
| 60±10.1 56.3±10.6 | paroxysmal | 48±4.2 44.2±5.6 | 135±54 178±43 | 46±29 48±23 | na na | 268±176 days 266±184 days | 65.3 65.6 |
| Gal et al.37 | PVAC:230
RF+Carto: 230
| 56.6±10.3 56.1±9.8 | 83.9:16.1 80:20 | 41.7±4.7 40.6±4.9 | 133.9±38.8 177.7±48.7 | 31.9±12.3 29.7±12.3 | 99.8 99.6 | 43 months | 47.7 45.5 |
| McReady et al. 38 | PVAC:94
RF+Carto or NAVx: 94
| 58±12
62±11
| paroxysmal | 38±7 39±5 | 140±43 167±42 | 35±16 42±20 | 98
97
| 12months | 60
56
|
OngoingTrials with Phased RF Ablation
The PRECISION GOLD Study is a prospective multi-center
trial, the main objective of which is to evaluate the incidence of
asymptomatic cerebral lesions after PVI using the new PVAC Gold
for PVI in patients with paroxysmal AF. The trial was completed last
year and full-length publication is expected during 2015.
The ongoing VICTORY AF (ClinicalTrials.gov Identifier:
NCT01693120) is a prospective global, multi-center, single-arm,
controlled, unblinded, investigational clinical study, with the purpose
of evaluating the risks of procedure and/or device-related strokes in subjects with persistent or long-standing persistent atrial AF
undergoing ablation with the Phased RF System. Patient enrollment
in US and European centers has already started.
Phased RF ablation involves the use of anatomically designed,
multi-electrode catheters with tissue temperature monitoring and a
closed-loop power control generator to create contiguous lesions in a
simpler procedure as compared with conventional AF ablation. The
majority of the literature data relate to PVI with the PVAC in patients
with paroxysmal AF. Similar acute and longer-term success rates,
but significantly lower procedure and fluoroscopy times with PVAC
ablation have consistently been reported relative to other AF ablation
methods. The incidence of manifest and silent cerebral complications
has fallen significantly in recent reports, thanks to important
changes in the periprocedural anticoagulation regime, procedural
modifications and improvements in software regulations of the RF
generator. Evaluation of the new PVAC Gold catheter is currently in
progress. Data from some studies suggest a short learning curve and
favorable results with this technology, even in lower-volume centers
and in the hands of operators with limited experience in AF ablation.
The safety and efficacy outcomes of phased RF ablation, including
mapping and ablation of arrhythmogenic drivers in the LA, body in
addition to PVI in patients with persistent AF are currently being
evaluated in the ongoing VICTORY AF trial.
